Patient-specific genomic features, including programmed cell death ligand 1 (PD-L1) expression, microsatellite instability (MSI), DNA repair gene mutations, and tumor mutational burden (TMB), are increasingly central to optimizing immunotherapy for prostate cancer. Here, CD274 is linked to neoplasm.